Finance

Beta
Lists
AARD:NASDAQ
Aardvark Therapeutics Inc
$5.76
+11.20%
(+0.58) 1D
$5.76
0.00% (0.00)
After hours
Closed: Jun 30, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AARD...
Open
$5.15
High
$5.78
Low
$5.00
Mkt. cap
125.66M
Avg. vol.
225.54K
Volume
228.32K
52-wk high
$17.94
52-wk low
$3.35
EPS
-$3.21
Shares outstanding
21.82M
No. of employees
40
Open
$5.15
High
$5.78
Low
$5.00
Mkt. cap
125.66M
Avg. vol.
225.54K
Volume
228.32K
52-wk high
$17.94
52-wk low
$3.35
EPS
-$3.21
Shares outstanding
21.82M
No. of employees
40
News stories
From sources across the web
About Aardvark Therapeutics Inc
CEO-
Employees40
Founded2017
Headquarters-
SectorPharmaceutical industry
Websiteaardvarktherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to AARD in the past 3 months
Hold
Buy
2
Hold
2
Sell
2
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AARD in the last 3 months.
Highest
Current $5.76
$7.00 (+21.53%)
Average
$5.00 (-13.19%)
Lowest
$3.00 (-47.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Wood
B. Riley Securities
Buy
Maintained
$7.00
+21.5%
05/15/2026
Jeet Mukherjee
BTIG
Hold
Downgraded
-
-
05/15/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
05/15/2026
Michael Ulz
Morgan Stanley
Sell
Downgraded
$3.00
-47.9%
05/15/2026
Tazeen Ahmad
Bank of America Securities
Sell
Downgraded
$4.00
-30.6%
05/15/2026
Tim Anderson
Bank of America Securities
Buy
Reiterated
$18.00
+212.5%
05/08/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$6.00
+4.2%
05/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$45.00
+681.3%
03/02/2026
Ram Selvaraju
H.C. Wainwright
Hold
Downgraded
-
-
03/02/2026
James Condulis
Stifel Nicolaus
Hold
Downgraded
$6.00
+4.2%
03/02/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$21.00
+264.6%
02/27/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.99 / -$0.92
-8.11%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
13.14M
13.74M
14.30M
16.57M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.70M
3.97M
4.40M
5.90M
Operating expense
15.85M
17.70M
18.70M
22.46M
Total operating expenses
15.85M
17.70M
18.70M
22.46M
Operating income
-15.85M
-17.70M
-18.70M
-22.46M
Other non operating income
-
-
-
-
EBT including unusual items
-14.37M
-16.32M
-17.60M
-21.59M
EBT excluding unusual items
-14.36M
-16.35M
-17.58M
-21.58M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.37M
-16.32M
-17.60M
-21.59M
Net profit margin
-
-
-
-
Earnings per share
-0.66
-0.75
-0.81
-0.99
Interest and investment income
1.49M
1.35M
1.12M
889.00K
Interest expense
-
-
-
-
Net interest expenses
1.49M
1.35M
1.12M
889.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.84M
-17.69M
-18.69M
-22.45M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer